Many of the biggest U.S. companies have pledged to invest trillions of dollars in the United States since President Donald Trump started his second term — including six names in our portfolio. These moves are aimed at aligning companies with the president's vision for a new global trade order designed to bring manufacturing jobs back from overseas and to address what he considers decades of unfair tariff barriers abroad. We have been keeping track of these promises, and new companies are being added to the list every day. Here is a rundown of six portfolio names, in alphabetical order, that have committed to major investments in the U.S., and how they see their businesses evolving on the shifting trade landscape. Abbott Laboratories : Abbott last month pledged $500 million to upgrade the manufacturing capabilities at plants in Illinois and Texas and to expand research and development (R & D). About 200 new jobs are expected in Illinois and 100 in Texas, a company spokesperson told Bloomberg. This is part of Abbott's short-term plan to mitigate tariff impacts, which management estimates to be a "few hundred million dollars." In a volatile year for stocks, Abbott has gained more than 19% year to date. It is the Club's second-best performing in 2025. Apple : As part of its commitment to invest $500 billion in the U.S. over four years, Apple said in February that it will open a new factory for artificial intelligence servers in Houston, Texas. The 250,000-square-foot facility is slated to open next year. Apple also plans to onboard about 20,000 new hires across the country over four years. More recently, CEO Tim Cook said on last week's earnings call that teams and facilities will expand in states including Michigan, California, and Texas. Assuming current tariff levels, Cook estimated $900 million in added costs in the June quarter but would not hazard a guess beyond that. Apple has dropped nearly 21% year to date. It is our worst-performing stock in 2025. Other than Club name Nvidia , Apple has the most to lose if the U.S.-China tensions don't improve. Bristol Myers Squibb : The drugmaker will invest $40 billion in the U.S. over the next five years, expanding its R & D and manufacturing footprint in the country. Bristol Myers CEO Christopher Boerner said in an op-ed Monday that funds will go across research and development, technology, and domestic manufacturing. "Through this investment plan, we will strengthen our presence across the country, ramp up radiopharmaceutical manufacturing, and invest in artificial intelligence and machine learning to help us significantly increase the pace of innovation," Boerner wrote. Last month, when releasing earnings, Bristol Myers hiked guidance and said it accounts for existing tariffs on U.S. products imported into China. The stock has fallen more than 16% year to date. It is our second worst in 2025. Eaton : The global power management company revealed plans in February to add a new transformer manufacturing facility in Jonesville, South Carolina. The operations there will support data centers, grid modernization as well as electrification and industrialization. Eaton will spend $340 million to increase U.S. production of its three-phase transformers. Eaton has invested more than $1 billion in manufacturing for electrical solutions in North America since 2023. Incoming CEO Paulo Ruiz said on last week's earnings call that the company aims to manage through the tariffs by adjusting costs, supply chains, and prices as needed. Eli Lilly : Lilly is looking to grow its domestic presence , with four new pharmaceutical manufacturing sites. Announced in February, this $27 billion investment pushes Eli Lilly 's total capital expansion commitments in the United States to over $50 billion since 2020. Lilly expects the four new locations to bring more than 3,000 jobs, including engineers, scientists, operations personnel, and lab technicians. Like Bristol Myers, Lilly is still waiting to hear whether Trump will put industry-specific tariffs on pharma. The president and administration officials have hinted that they are coming. On last week's earnings call, Lilly management said they expect announced tariffs will have "limited impact financially, which we have absorbed within our 2025 guide" of sales between $58 billion and $61 billion. Shares of Lilly have fallen roughly 1.5% year to date. They would have been much higher if not for their big slide that started last week on news of a partnership between CVSHealth and rival Novo Nordisk on weight loss drugs. Nvidia : Through partnerships with Taiwan Semiconductor Manufacturing , Foxconn, Wistron and others, Nvidia pledged to produce up to $500 billion worth of AI infrastructure in the U.S. over four years. Production of some of the company's Blackwell chips has started at TSMC's plant in Phoenix. Nvidia is also building supercomputer manufacturing plants with Foxconn in Houston and Wistron in Dallas. Production is expected to increase in the next 12 to 15 months at both facilities. Shares of Nvidia, which doesn't report earnings until May 28, have dropped 12% year to date. Late Wednesday, Nvidia investors breathed a sigh of relief after the Trump administration scrapped the implementation of a controversial Biden-era rule on AI chip exports. Last month, however, Trump tightened another Biden chip export rule, saying slower, made-for-China chips need a license. Consequently, Nvidia on April 15 said it would book a $5.5 billion inventory charge . (Jim Cramer's Charitable Trust is long AAPL, ABT, BMY, LLY, ETN, NVDA. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
